Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026)
Inhibikase Therapeutics (IKT) recorded Research & Development of $13.39 million in Q2 2026, up 154.1% from $5.27 million a year earlier and up 23.6% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026) Analysis & Trends
On a TTM basis, Inhibikase Therapeutics' Research & Development came in at $38.24 million as of Jun 30, 2026, up 40.8% year-over-year; for FY2025, it was $29.79 million, up 73.1% from FY2024.
- Annual Research & Development has increased for four straight years, with a five-year compound annual growth rate of 101.6% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $17.21 million in FY2024 (+26.4%), $13.62 million in FY2023 (+13.2%), $12.03 million in FY2022 (+6.0%) and $11.36 million in FY2021.
- The Q2 2026 figure is the highest quarterly Research & Development in data going back to Q1 2020.
- On a year-over-year basis, Research & Development rose in seven of the last eight quarters, with growth averaging 93.9%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 282.1% in Q1 2025, against a decline of 32.2% in Q2 2024 at the low end.
- Per Business Quant, the preceding three quarters came in at $10.84 million (Q1 2026), $6.36 million (Q4 2025) and $7.65 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Inhibikase Therapeutics | 288.92 Mn | -296.56 Mn | - | 13.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.39 Mn |
| Mar 31, 2026 | 10.84 Mn |
| Dec 31, 2025 | 6.36 Mn |
| Sep 30, 2025 | 7.65 Mn |
| Jun 30, 2025 | 5.27 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 7.19 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Dec 31, 2023 | 3.00 Mn |
| Sep 30, 2023 | 3.23 Mn |
| Jun 30, 2023 | 4.54 Mn |
| Mar 31, 2023 | 2.85 Mn |
| Dec 31, 2022 | 3.05 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Jun 30, 2022 | 2.98 Mn |
| Mar 31, 2022 | 3.02 Mn |
| Dec 31, 2021 | 3.39 Mn |
| Sep 30, 2021 | 3.15 Mn |
API Access
Inhibikase Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();